# Electron-Induced Fragmentation of 5-Iodouridine: Implications for Enhanced Radiotherapy

**Authors:** Janina Kopyra, Paulina Wierzbicka, Hassan Abdoul-Carime

PMC · DOI: 10.1021/acs.jpclett.5c01615 · The Journal of Physical Chemistry Letters · 2025-10-03

## TL;DR

This paper shows how 5-iodouridine breaks apart when hit by electrons during radiation, which could make cancer treatments more effective.

## Contribution

The study reveals a new mechanism of radiosensitization via electron-induced fragmentation of 5-iodouridine.

## Key findings

- Low-energy electrons efficiently dissociate 5-iodouridine into reactive fragments.
- 5-iodouridine causes significantly more DNA damage compared to thymidine and 5-fluorouridine.
- The findings suggest combining 5-iodouridine with cisplatin or gold nanoparticles could enhance radiotherapy.

## Abstract

5-Iodouridine is
a known and potentially efficient radiosensitizer;
however, it has not been considered for clinical use because of its
poor metabolic incorporation into DNA. Recent development of a novel
pro-drug, ropidoxuridine, has improved the bioavailability of this
halogenated nucleoside, although the exact mechanism of its radiosensitizing
action remains not fully elucidated. Here, we demonstrate that low-energy
electronsabundantly generated along radiation tracksefficiently
dissociate the halogenated nucleoside via the primary pathway (99%),
producing an iodine anion and a uridine-yl• neutral
radical, with a high approximate DEA cross section of (2.7 ±
1.9)×10–14 cm2. The latter, known
to be highly reactive, subsequently induces hydrogen abstraction,
leading to DNA strand breaks. The damage induced in 5IUrd by low-energy
electrons is found to be about 700 times greater than that in thymidine
and about 4 times that of the clinically used 5-fluorouridine. These
findings may contribute to the development of future cancer therapy
strategies by synergistically combining 5IUrd with cisplatin or gold
nanoparticles, which act as a source of secondary low-energy electrons
during radiation therapy.

## Linked entities

- **Chemicals:** 5-Iodouridine (PubChem CID 1268108), ropidoxuridine (PubChem CID 9840777), cisplatin (PubChem CID 5460033), 5-fluorouridine (PubChem CID 9427), thymidine (PubChem CID 5789)
- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Diseases:** cancer (MESH:D009369)
- **Chemicals:** 5IUrd (-), 5-fluorouridine (MESH:C001943), hydrogen (MESH:D006859), gold (MESH:D006046), 5-Iodouridine (MESH:C035991), thymidine (MESH:D013936), cisplatin (MESH:D002945), ropidoxuridine (MESH:C045889)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12536442/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12536442/full.md

## References

63 references — full list in the complete paper: https://tomesphere.com/paper/PMC12536442/full.md

---
Source: https://tomesphere.com/paper/PMC12536442